<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363711">
  <stage>Registered</stage>
  <submitdate>15/02/2013</submitdate>
  <approvaldate>18/02/2013</approvaldate>
  <actrnumber>ACTRN12613000190707</actrnumber>
  <trial_identification>
    <studytitle>Does statin use have a disease modifying effect in symptomatic knee osteoarthritis? A multicentre randomised, double-blind, placebo-controlled trial</studytitle>
    <scientifictitle>Does statin use reduce the rate of knee cartilage volume loss in symptomatic knee osteoarthritis? A multicentre randomised, double-blind, placebo-controlled trial</scientifictitle>
    <utrn />
    <trialacronym>OAKS Study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>knee osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>40 mg of atorvastatin (oral tablet) once daily over 2 years</interventions>
    <comparator>40 mg of placebo (with no active ingredients) once daily over 2 years</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Annual change in tibial cartilage volume, assessed from knee MRI</outcome>
      <timepoint>2 years after intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression of cartilage defects, assessed from knee MRI</outcome>
      <timepoint>2 years after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression of bone marrow lesions, assessed from knee MRI</outcome>
      <timepoint>2 years after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in knee symptoms and function, assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</outcome>
      <timepoint>2 years after intervention commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Males and females with symptomatic knee osteoarthritis for at least 6 months with a pain score at least 20 mm on a 100 mm visual analogue scale;
2. Age 40-70 years old;
3. Meet the America College of Rheumatology criteria for symptomatic knee osteoarthritis.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Inability to give informed consent;
2) Patients with severe radiographic knee osteoarthritis (grade 3 according to Altmans atlas) or severe knee pain (on standing &gt; 80 mm on a 100 mm visual analogue scale);
3) Patients with rheumatoid arthritis, other inflammatory arthritis, or significant knee injury;
4) Patients in whom statins are indicated for familial hypercholesterolaemia, cardiovascular disease, diabetes, taking current lipid-lowering therapy, or with previous adverse reaction to statins;
5) Patients with absolute cardiovascular risk assessed using the Framingham Risk Equation of more than 15% within the next 5 years (National Heart Foundation of Australia, 2005);
6) Patients with clinically significant renal disease or aspartate aminotransferase, alanine aminotransferase, or creatine kinase more than twice the upper limit of laboratory normal range;
7) Patients undergoing arthroscopy or open surgery in the index knee in the last 12 months;
8) Patients receiving intra-articular therapy in the index knee in the last 12 months;
9) Concomitant use of potent analgesics including opiates;
10) Co-morbidity that may limit participation (e.g. planned index knee joint replacement, medical conditions e.g. malignancy in the past 5 years other than non-melanoma skin cancer) or relocation;
11) Any contraindication to MRI scanning (e.g. implanted pacemaker, metal sutures, presence of shrapnel or iron filings in the eye, or claustrophobia).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation is done based on computer generated random numbers prepared by a statistician with no involvement in the trial. Block randomisation is performed, stratified according to the study sites.
</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/03/2013</anticipatedstartdate>
    <actualstartdate>26/08/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>4/02/2016</actualenddate>
    <samplesize>350</samplesize>
    <actualsamplesize>308</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>4/02/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,TAS,VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Yuanyuan Wang</primarysponsorname>
    <primarysponsoraddress>Department of Epidemiology &amp; Preventive Medicine
Monash University, The Alfred Hospital
99 Commercial Road
Melbourne VIC 3004
Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>Level 1, 16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Flavia Cicuttini</sponsorname>
      <sponsoraddress>Department of Epidemiology &amp; Preventive Medicine
Monash University, The Alfred Hospital
99 Commercial Road
Melbourne VIC 3004
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Andrew Tonkin</sponsorname>
      <sponsoraddress>Department of Epidemiology &amp; Preventive Medicine
Monash University, The Alfred Hospital
99 Commercial Road
Melbourne VIC 3004
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Graeme Jones</sponsorname>
      <sponsoraddress>Private Bag 23, Menzies Research Institute
Hobart TAS 7000
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Catherine Hill</sponsorname>
      <sponsoraddress>The Queen Elizabeth Hospital
28 Woodville Road
Woodville SA 5011
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Changhai Ding</sponsorname>
      <sponsoraddress>Private Bag 23, Menzies Research Institute
Hobart TAS 7000
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Anita Wluka</sponsorname>
      <sponsoraddress>Department of Epidemiology &amp; Preventive Medicine
Monash University, The Alfred Hospital
99 Commercial Road
Melbourne VIC 3004
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this randomised controlled trial is to determine whether statins slow the progression of knee osteoarthritis. The hypothesis is that atorvastatin use will reduce the rate of knee cartilage volume loss over 2 years compared with placebo in people with symptomatic knee osteoarthritis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>Ethics &amp; Research Governance
Ground Floor, Linay Pavilion
55 Commercial Road
Melbourne, VIC 3004
Australia</ethicaddress>
      <ethicapprovaldate>5/02/2013</ethicapprovaldate>
      <hrec>521/12</hrec>
      <ethicsubmitdate>19/11/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Tasmania Health &amp; Medical Human Research Ethics Committee</ethicname>
      <ethicaddress>Building 1
301 Sandy Bay Road, Sandy Bay
Hobart, TAS 7001</ethicaddress>
      <ethicapprovaldate>7/02/2013</ethicapprovaldate>
      <hrec>H0012971</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Human Research Ethics Committtee (TQEH/LMH/MH)</ethicname>
      <ethicaddress>Basil Hetzel Institute DX465101
The Queen Elizabeth Hospital
28 Woodville Road
Woodville South SA 5011</ethicaddress>
      <ethicapprovaldate>22/01/2014</ethicapprovaldate>
      <hrec>HREC/13/TQEHLMH/20</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Yuanyuan Wang</name>
      <address>Department of Epidemiology &amp; Preventive Medicine
Monash University, The Alfred Hospital
99 Commercial Road
Melbourne VIC 3004
Australia</address>
      <phone>+61 3 99030353</phone>
      <fax />
      <email>yuanyuan.wang@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Flavia Cicuttini</name>
      <address>Department of Epidemiology &amp; Preventive Medicine
Monash University, The Alfred Hospital
99 Commercial Road
Melbourne VIC 3004
Australia</address>
      <phone>+61 3 99030158</phone>
      <fax />
      <email>flavia.cicuttini@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Flavia Cicuttini</name>
      <address>Department of Epidemiology &amp; Preventive Medicine
Monash University, The Alfred Hospital
99 Commercial Road
Melbourne VIC 3004
Australia</address>
      <phone>+61 3 99030158</phone>
      <fax />
      <email>flavia.cicuttini@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yuanyuan Wang</name>
      <address>Department of Epidemiology &amp; Preventive Medicine
Monash University, The Alfred Hospital
99 Commercial Road
Melbourne VIC 3004
Australia</address>
      <phone>+61 3 99030353</phone>
      <fax />
      <email>yuanyuan.wang@monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>